BDX vs STVN: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: BDX is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BDX and STVN share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BDX and STVN exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Becton, Dickinson and Company, known as BD, is one of the largest medical technology companies in the world, founded in 1897 and headquartered in Franklin Lakes, New Jersey. Most of what it sells is consumable rather than capital equipment: needles and syringes, IV catheters and vascular access sets, infusion pumps and their disposable sets, surgical and specimen-collection products, prefillable syringes sold to pharmaceutical companies, and interventional devices used in urology, peripheral vascular and surgery. That mix matters because consumables are consumed and reordered, so a large share of revenue recurs each year regardless of hospital capital budgets. Following the February 2026 separation, BD reports in four segments: Medical Essentials (~$1.68 billion in the June 2026 quarter), Interventional (~$1.41 billion), Connected Care (~$1.22 billion) and BioPharma Systems (~$0.67 billion).

Full BDX guide

Stevanato Group has been making pharmaceutical glass in Piombino Dese, near Padua in northern Italy, since 1949, and sells its containers under the Ompi brand. The business runs in two segments. Biopharmaceutical and Diagnostic Solutions covers vials, syringes, cartridges, EZ-fill ready-to-use containers and the Alina pen injector platform, and produced ~EUR 266.2 million of the ~EUR 302.0 million total in the second quarter of 2026. Engineering builds the assembly, visual inspection and glass converting machinery that drug makers and other packaging firms use on their own lines, and contributed the remaining ~EUR 35.8 million. The company listed ordinary shares on the New York Stock Exchange in July 2021, but it remains an Italian issuer that reports in euros and files as a foreign private issuer, and the founding family retains roughly four fifths of the shares through Stevanato Holding S.r.l., with Italian loyalty-share rules adding extra votes on top of that.

Full STVN guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BDX drivers: A simpler, pure-play medtech after the Waters separation; BioPharma Systems and injectable drug delivery.
• STVN drivers: The high-value solutions mix shift; Injectable biologics volumes, GLP-1 included.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The most persistent risk is product liability: BD carries large ongoing litigation over hernia and pelvic mesh and IVC filters, and adverse verdicts or settlement waves can hit cash flow and headlines unpredictably. For STVN, customer destocking has hit this company before and can again: after the May 2024 guidance cut on industry-wide vial destocking the shares fell ~22% in a single session, and several plaintiff firms opened investigations afterward (as of August 2026 no securities class action complaint with a case number appears to have been filed, so those remain investigations rather than litigation).

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BDX if you believe its drivers more; STVN if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BDX and STVN guides.

BDX. All figures are approximate and tied to the asOf date; check live numbers before acting on any of them. The wide gap between the trailing GAAP multiple (~30x) and the forward multiple (~13x to ~14x) is not a growth forecast, it is mostly an artifact of separation charges, intangible amortization and discontinued-operations accounting depressing reported GAAP earnings, which is why BD and most analysts discuss adjusted EPS. Trailing revenue comparisons across fiscal 2025 and fiscal 2026 are not like-for-like, because the Biosciences and Diagnostic Solutions business moved to discontinued operations after the February 2026 close.

STVN. Every operating figure above is reported in euros because Stevanato is an Italian issuer, while the share price and market capitalization are quoted in US dollars on the NYSE, so the two sets of numbers move on different currencies and should not be compared directly. A trailing multiple near ~40 times sits well above the growth rate of the overall business at ~8%, which only makes sense if the high-value solutions line keeps compounding in the mid teens and pulls group margins with it. The guided free cash flow range of breakeven to ~EUR 20 million for 2026 is the reminder that the capacity build is still consuming what the operations generate.

Headline figures (approximate, August 2026): BDX shows revenue (ttm, continuing operations) ~$20.8 billion, q3 fiscal 2026 revenue (quarter ended june 2026) ~$5.0 billion, up ~5.4% as reported and ~4.4% currency-neutral, q3 fiscal 2026 eps ~$1.64 GAAP diluted from continuing operations, ~$3.23 adjusted, fiscal 2026 guidance (adjusted diluted eps) ~$12.62 to ~$12.72, with low-single-digit-plus revenue growth; STVN shows revenue (ttm) ~EUR 1.20 billion (about ~$1.40 billion), q2 2026 revenue ~EUR 302.0 million, up ~8% year over year, q2 2026 margins gross ~28.7%, adjusted EBITDA ~26.0%, adjusted diluted EPS ~EUR 0.14, fy2026 company guidance revenue ~EUR 1.260 to ~EUR 1.280 billion, adjusted diluted EPS ~EUR 0.60 to ~EUR 0.62.

BDX and STVN are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BDX and STVN exposure against your real portfolio. It is not an investment adviser.